You are here: Welcome to the MPKB » Welcome to the MPKB » Starting the Marshall Protocol » Safety warnings for the Marshall Protocol
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:starting:safety_warnings [09.15.2017] – [Patients must understand the Marshall Protocol] + telmisartan angerdis sallieqhome:starting:safety_warnings [09.15.2017] – [Notes and comments] sallieq
Line 89: Line 89:
   * added "Xarelto increases the risk of bleeding and can cause serious or fatal bleeding. A specific antidote for rivaroxaban is not available. Because of high plasma protein binding, rivaroxaban is not expected to be dialyzable." --Sallie Q May15    * added "Xarelto increases the risk of bleeding and can cause serious or fatal bleeding. A specific antidote for rivaroxaban is not available. Because of high plasma protein binding, rivaroxaban is not expected to be dialyzable." --Sallie Q May15 
   * altered 3rd line to 'sufficient olmesartan medoxomil (Benicar) to ensure that patient does not run out if there is a delay in delivery or in renewing prescription' --- //Sallie Q 11.02.2016//   * altered 3rd line to 'sufficient olmesartan medoxomil (Benicar) to ensure that patient does not run out if there is a delay in delivery or in renewing prescription' --- //Sallie Q 11.02.2016//
 +
 +alteration ( @ Patients must understand..) why the use of  telmisartan or azithromycin is considered particularly dangerous  --- //Sallie Q 09.15.2017//
home/starting/safety_warnings.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.